Alessio Maria Edoardo Maraglino, Simona Sammassimo, Ginevra Lolli, Alice Clemente, Valentina Tabanelli, Rocco Pastano, Enrico Derenzini
{"title":"达拉单抗联合硼替佐米和地塞米松作为难治性t细胞淋巴母细胞淋巴瘤同种异体移植的桥梁。","authors":"Alessio Maria Edoardo Maraglino, Simona Sammassimo, Ginevra Lolli, Alice Clemente, Valentina Tabanelli, Rocco Pastano, Enrico Derenzini","doi":"10.1007/s00277-025-06474-z","DOIUrl":null,"url":null,"abstract":"<p><p>Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We administered a salvage treatment with daratumumab in combination with bortezomib and dexamethasone regimen followed by allogeneic stem cell transplantation from HLA-haploidentical related donor in a 50 years old patient affected by cortical CD38 positive T-LBL, refractory to 2 prior therapies including first-line cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone (hyper-CVAD) regimen plus autologous stem cell transplantation. After 29 months he is alive and in sustained complete remission, emphasizing the role of daratumumab in combination with bortezomib and dexamethasone as a salvage treatment option in CD38 positive r/r T-LBL patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.\",\"authors\":\"Alessio Maria Edoardo Maraglino, Simona Sammassimo, Ginevra Lolli, Alice Clemente, Valentina Tabanelli, Rocco Pastano, Enrico Derenzini\",\"doi\":\"10.1007/s00277-025-06474-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We administered a salvage treatment with daratumumab in combination with bortezomib and dexamethasone regimen followed by allogeneic stem cell transplantation from HLA-haploidentical related donor in a 50 years old patient affected by cortical CD38 positive T-LBL, refractory to 2 prior therapies including first-line cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone (hyper-CVAD) regimen plus autologous stem cell transplantation. After 29 months he is alive and in sustained complete remission, emphasizing the role of daratumumab in combination with bortezomib and dexamethasone as a salvage treatment option in CD38 positive r/r T-LBL patients.</p>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00277-025-06474-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06474-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.
Relapsed and refractory (r/r) T-cell lymphoblastic lymphoma (T-LBL) is a highly lethal disease, with no effective treatment options. Daratumumab, an anti-CD38 human IgG1κ monoclonal antibody has been used as single agent in CD38 positive r/r T-LBL. We administered a salvage treatment with daratumumab in combination with bortezomib and dexamethasone regimen followed by allogeneic stem cell transplantation from HLA-haploidentical related donor in a 50 years old patient affected by cortical CD38 positive T-LBL, refractory to 2 prior therapies including first-line cyclophosphamide, vincristine, doxorubicin hydrochloride and dexamethasone (hyper-CVAD) regimen plus autologous stem cell transplantation. After 29 months he is alive and in sustained complete remission, emphasizing the role of daratumumab in combination with bortezomib and dexamethasone as a salvage treatment option in CD38 positive r/r T-LBL patients.
期刊介绍：
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
